论文标题
共核干细胞疗法的当前抗急性呼吸窘迫综合征的景观
Current Landscape of Mesenchymal Stem Cell Therapy in COVID Induced Acute Respiratory Distress Syndrome
论文作者
论文摘要
2019年底，严重的急性呼吸综合症冠状病毒2疫情爆发现已创造出一种全球大流行，已扩散到150多个国家。在大多数人中，Covid 19是一种呼吸道感染，会产生发烧，咳嗽和呼吸急促。患有严重的共同Covid 19的患者可能会出现ARDS。 MSC可以来自许多地方，例如骨髓，脐带和脂肪组织。由于其易于访问性和低免疫原性，MSC经常用于动物和临床研究。在最近的研究中，MSC已显示可减少炎症，增强肺渗透性，改善微生物和肺泡液清除率，并加速肺上皮和内皮修复。此外，基于MSC的治疗在链球研究和败血症和ARDS中的1阶段临床试验中表现出了有希望的结果。在本文中，我们使用MSC提出了治疗策略，并剖析了如何以及为什么MSC治疗是Covid 19引起的ARDS的潜在治疗选择。我们引用了许多有前途的临床试验，阐明了MSC治疗19 ARDS患者的潜在优势，研究了这种治疗策略的损害，并提出了随后的研究的可能性。
The severe acute respiratory syndrome coronavirus 2 outbreak in Chinas Hubei area in late 2019 has now created a global pandemic that has spread to over 150 countries. In most people, COVID 19 is a respiratory infection that produces fever, cough, and shortness of breath. Patients with severe COVID 19 may develop ARDS. MSCs can come from a number of places, such as bone marrow, umbilical cord, and adipose tissue. Because of their easy accessibility and low immunogenicity, MSCs were often used in animal and clinical research. In recent studies, MSCs have been shown to decrease inflammation, enhance lung permeability, improve microbial and alveolar fluid clearance, and accelerate lung epithelial and endothelial repair. Furthermore, MSC-based therapy has shown promising outcomes in preclinical studies and phase 1 clinical trials in sepsis and ARDS. In this paper, we posit the therapeutic strategies using MSC and dissect how and why MSC therapy is a potential treatment option for COVID 19 induced ARDS. We cite numerous promising clinical trials, elucidate the potential advantages of MSC therapy for COVID 19 ARDS patients, examine the detriments of this therapeutic strategy and suggest possibilities of subsequent research.
